BioSenic
For autoimmune, inflammatory and bone diseases.
Launch date
Employees
Market cap
€2.2m
Enterprise valuation
€30m (Public information from Sep 2024)
Share price
€0.0081 BIOS.BR
Mont-Saint-Guibert Walloon Brabant (HQ)
Financials
Estimates*
| EUR | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Revenues | - | 1.0m | 1.0m | - | - | - |
| EBITDA | (8.9m) | (14.5m) | (11.8m) | (2.3m) | (8.0m) | (11.3m) |
| % EBITDA margin | - | (1448 %) | (1181 %) | - | - | - |
| Profit | (10.5m) | (11.9m) | (12.9m) | (2.0m) | (28.8m) | (11.2m) |
| % profit margin | - | (1194 %) | (1293 %) | - | - | - |
| EV / EBITDA | - | - | - | -4.2x | -4.7x | -2.8x |
| R&D budget | 11.2m | 15.4m | 11.7m | 1.0m | 3.9m | - |
| R&D % of revenue | - | 1542 % | 1168 % | - | - | - |
| Date | Investors | Amount | Round |
|---|---|---|---|
| N/A | N/A | IPO | |
* | N/A | €500k | Private Placement VC |
* | €1.0m | Post IPO Equity | |
* | €15.5m | Post IPO Debt | |
* | €1.2m | Post IPO Convertible | |
* | N/A | €2.1m | Post IPO Debt |
| Total Funding | €500k | ||